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Introduction: The existence of breast cancer stem-like cells (BCSCs) has profound implications for cancer
prevention. Genistein, a predominant isoflavone found in soy products, has multiple robust anti-tumor effects in
various cancers, especially in the breast and prostate cancer. In this study, we aimed to evaluate genistein inhibition
of BCSCs and its potential mechanism by culturing MCF-7 breast cancer cells and implanting these cells into
nude mice.
Methods: Cell counting, colony formation and cell apoptosis analysis were used to evaluate the effect of genistein
on breast cancer cells’ growth, proliferation and apoptosis. We then used mammosphere formation assay and
CD44CD24 staining to evaluate the effect of genistein on BCSCs in vitro. A nude mice xenograft model was
employed to determine whether genistein could target BCSCs in vivo, as assessed by real-time polymerase chain
reaction (PCR) and immunohistochemical staining. The potential mechanism was investigated utilizing real-time
PCR, western blotting analysis and immunohistochemical staining.
Results: Genistein inhibited the MCF-7 breast cancer cells’ growth and proliferation and promoted apoptosis. Both
in vitro and in vivo genistein decreased breast cancer stem cells, and inhibited breast cancer stem-like cells through
down-regulation of the Hedgehog-Gli1 Signaling Pathway.
Conclusions: We demonstrated for the first time that genistein inhibits BCSCs by down-regulating Hedgehog-Gli1
signaling pathway. These findings provide support and rationale for investigating the clinical application of
genistein in treating breast cancer, and specifically by targeting breast cancer stem cells.Introduction
Breast cancer remains one of the most commonly diag-
nosed cancers in the world. In Asian countries, particu-
larly China and Japan, presumably due to diet and other
environmental factors, the incidence of breast cancer is
significantly lower than that in the western countries.
Recent epidemiological and experimental studies have
provided convincing evidence that genistein in soy-rich
food contribute to the lower breast cancer incidence
[1-3]. Genistein (4,5,7-trihydroxyisoflavone), a natural
isoflavone phytoestrogen found in soybeans, has multiple
functions on antitumor effects [4]. Additionally, it has* Correspondence: lilianhong917@126.com
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reproduction in any medium, provided the orbeen suggested that genistein can overcome cancer drug
resistance and inhibit cancer relapse/recurrence [4,5].
Many human tumors contain cancer stem cells, which
possess the self-renewal capacity, chemoresistance and
an enhanced tumorigenicity [6]. In fact, the concept that
cancers arise from stem cells or germ cells was first pro-
posed almost 150 years ago. Cancer stem cells are now
thought to play key roles in cancer growth, metastasis,
and relapse. There has been compelling evidence that
many cancer types, including breast cancer, are initiated
from and maintained by a small population of cancer
stem cells [7,8]. Breast cancer stem-like cells (BCSCs)
are a small population of mostly resting cells defined by
their long life, high clonogenicity, self-replicating poten-
tial, plasticity, and drug resistance [9]. A novel breast
cancer combined chemotherapy and radiotherapy strat-
egy that targets BCSCs has received extensive attention.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pounds are promising chemoprevention agents against
cancer stem cells, such as sulforaphane and curcumin
[10,11]. Montales and colleagues were the first to dem-
onstrate that genistein inhibition of mammosphere for-
mation was mimicked by the Akt inhibitor perifosine
and was associated with enhanced tumor suppressor
phosphatase and tensin homolog deleted on chromo-
some 10 (PTEN) expression [12]. Diets rich in fruits and
vegetables are implicated in breast cancer risk reduction,
yet underlying mechanisms are poorly understood. The
deregulation of some pathways is well known to inhibit
tumorigenesis involving cancer stem cell signaling path-
ways, such as Hedgehog, Notch, and Wnt/β-catenin in
breast cancer [13]. The Hedgehog pathway regulates the
embryonic development of both invertebrates and verte-
brates, and contributes to the formation of different organs
and tissues, including the neural tube. Three mammalian
homologs of this gene were subsequently identified: Sonic
hedgehog (Shh), Indian hedgehog and Desert hedgehog.
Shh is the most widely studied and best characterized [14].
The receptor Patched (Ptch) is a 12-transmembrane protein
that acts catalytically to inhibit the seven-transmembrane
protein Smoothened (Smo), rendering the pathway inactive
in the absence of Hedgehog ligand. Binding of Hedgehog
ligand inactivates Ptch, derepressing Smo and resulting in
positive Hedgehog pathway signaling. When Smo is in-
active, a multiprotein complex constitutively processes the
Gli proteins to short, transcriptionally repressive forms.
The Gli family contains Gli1, Gli2, and Gli3, which share
five highly conserved tandem C2H2 zinc finger domains
and a histidine–cysteine linker sequence between the zinc
fingers. In humans, Gli1 acts as an activator, Gli2 as an acti-
vator or as a repressor depending upon its catalytic, and
Gli3 as a repressor [15-17].
In the present study, we evaluated the efficacy and
mechanisms of genistein suppressing the population of
BCSCs from MCF-7 human breast cancer cells by exam-
ining tumor growth in vivo, mammosphere formation
in vitro, and Hedgehog pathway expression.
Materials and methods
Reagents
Genistein was obtained from Sigma-Aldrich (St Louis,
MO, USA), and dissolved in dimethyl sulfoxide (DMSO)
at different doses for the experiments. Equal treatment
volumes of DMSO were used as a vehicle control. All
other materials were of analytical grade and were ob-
tained from commercial sources.
Cell lines and cell proliferation assay
Human breast cancer cell line MCF-7 was purchased from
the Cell Bank of Type Culture Collection of Chinese
Academy of Sciences, Shanghai Institute of Cell Biology,Shanghai, China. The cells were respectively cultured in
Dulbecco’s modified Eagle’s medium (HyClone, Logan,
UT, USA) supplemented with 10% fetal bovine serum
(HyClone). All cells were maintained at 37°C, in 5% car-
bon dioxide and 95% relative humidity.
For growth inhibitory studies, MCF-7 cells were seeded
in 96-well plates at a density of 3 × 104 cells/well. The cells
were incubated with genistein at concentrations of 0, 2.5, 5,
10, 15, 20, 30, 50, and 70 μM for 48 hours. After adding the
solution of the Cell Counting Assay Kit-8 (Sigma-Aldrich)
to cells/well, the cells were incubated for another 2 hours.
The absorbance was measured with a microplate reader at
450 nm. The amount of the formazan dye, generated by the
activated dehydrogenases in cells, was directly proportional
to the number of living cells. Addition of medium alone
was used as the blank control group. To estimate the in-
hibitory rate of cell growth, the concentration that inhibits
50% of the growth of control cells was calculated. All exper-
iments were performed three times independently.
Colony formation assay
MCF-7 cells were treated with genistein at concentra-
tions from 0 to 15 μM for 48 hours. The viable cells
were counted and seeded for colony formation assay in
six-well plates at 300 cells/well. During colony growth,
the culture medium was replaced every 3 days. Colonies
with over 50 cells were counted under an inverted
microscope (Olympus, Japan) on day 7 after seeding, to
calculate the formation rate:
Colony formation rate ¼ number of colonies=number
of seeded cells  100%
Each experiment was carried out in triplicate.
Cell apoptosis analysis
Cell apoptosis was analyzed by flow cytometry. Briefly, 1 ×
106 cells were collected and washed in phosphate-buffered
saline after treatment with different concentration of genis-
tein for 48 hours. After washing with phosphate-buffered
saline, the cells were resuspended in 500 μl binding buffer
and incubated with 5 μl fluorescein isothiocyanate (FITC)–
Annexin-V (BD Biosciences, San Jose, CA, USA) and 10 μl
propidium iodide (BD Biosciences) for 15 minutes at 4°C
in the dark. Apoptosis was measured using flow cytometry
to quantify the levels of phosphatidylserine on the outer
membrane of apoptotic cells. The results were analyzed by
flow cytometry using the BD FACS Aria cell sorter (BD,
Franklin Lakes, NJ, USA). This experiment was repeated
three times.
Mammosphere formation assay
The mammosphere forming assay was performed as de-
scribed previously with slight modification [18]. Briefly,
the cells were plated in ultra-low-attachment six-well
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cells/ml in primary culture and 1,000 cells/ml in passages,
which were supplemented with 2 mmol/l l-glutamine
(ATCC, Manassas, VA), 2% B27 supplement (Invitrogen,
Carlsbad, CA, USA), 20 ng/ml human recombinant epi-
dermal growth factor (Sigma-Aldrich) and 20 ng/ml
basic fibroblast growth factor (Sigma-Aldrich), 4 μg/ml
heparin and 5 μg/ml insulin (Sigma-Aldrich). Mammo-
spheres were counted after culture for 7 days under a
Nikon Eclipse TE2000-S microscope (Japan) and photo-
graphs were acquired with Meta Morph.
CD44 and CD24 staining
The CD44+ and CD24– breast cancer cell population was
reported previously to include BCSCs [19]. After treat-
ment of genistein for 48 hours, the MCF-7 cells were
stained with phycoerythrin-conjugated anti-human CD24
antibody (Invitrogen) and FITC-conjugated anti-human
CD44 antibody (Invitrogen) according to the manufac-
turer’s instructions. Samples were analyzed using a FACS
Calibur flow cytometer and Cell Quest software (BD).
Tumor growth and morphologic analysis in vivo
All studies involving mice were approved by the Animal
Care and Use Committee of Dalian Medical University
(Dalian, China). Fifteen 6-week-old to 8-week-old female
nude mice were purchased from the Experimental Animal
Center of Dalian Medical University. Then 1 × 106 MCF-7
cells were suspended in 100 μl phosphate-buffered saline
mixed with matrigel (1:1) and injected into the mouse
mammary fat pad. Two weeks after cell injection, the mice
were randomly separated into three groups, which were in-
traperitoneally injected with control (0.1% DMSO solution)
or with 20 and 50 mg/kg genistein respectively (dissolved
in 0.1% DMSO solution) daily for 2 weeks. Tumors were
measured with a caliper, and the volume was calculated:
Volume = 1/2 (width2 × length)
The tumors were excised, weighed, and frozen at −80°C
until processing for RNA and protein isolation. For
histological study, portions of tumors were fixed in
10% neutral-buffered formalin, were paraffin embed-
ded, and then 4 μm sections were stained for immuno-
histologic assay.
Immunohistochemical staining
The tumor sections were deparaffinized in xylene and rehy-
drated with graded ethanol followed by microwave heating
for 30 minutes in 10 mM sodium citrate buffer (pH 7.2);
0.3% hydrogen peroxide solution was used for the block-
ing of endogenous peroxide activity. The primary mono-
clonal antibodies against aldehyde dehydrogenase isoform
1 (ALDH1; (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), human SMO (Santa Cruz Biotechnology), and Gli1
(Santa Cruz Biotechnology) were applied at 4°C overnight.The sections were incubated with horseradish peroxidase-
labeled goat anti-mouse/rabbit antibody (Maixin Bio) for
30 minutes at room temperature. 3,3′-Diaminobenzidine
was used as the chromogen and hematoxylin as the nu-
clear counterstain. The sections were dehydrated, cleared,
and mounted.
Western blotting analysis
For the western blot analysis, 1 × 106 cells incubated with
different concentrations of genistein for 48 hours were har-
vested and lysed. The protein concentration was determined
by the Bradford method with bovine serum albumin
(Sigma-Aldrich). Each sample was treated with anti-Smo
(Sigma-Aldrich) or anti-Gil1 (Santa Cruz, Inc.) primary anti-
bodies. Primary anti-bodies were detected by horseradish
peroxidase-conjugated antibody (1:2,000; GE Healthcare).
Signals were detected by the enhanced chemiluminescence
detection system (Amersham Pharmacia Biotech).
Real-time polymerase chain reaction
Total RNA was extracted from cell pellets using the Quick
Prep total-RNA Kit (Amersham Biosciences, UK), accord-
ing to the manufacturer’s instructions. Each sample was
incubated for 48 hours with different concentrations of
genistein. Reverse transcription was performed using a
Taq Man Reverse Transcription Kit (Applied Biosystems).
For quantitative real-time reverse transcription polymer-
ase chain reaction, 1 ml gene primers with the SYBR
Green RT-PCR Kit (QIAGEN, Valencia, CA, USA) in 20
ml reaction volume was applied. The relative changes in
the amount of transcripts in each sample were determined
by normalizing with the glyceraldehyde 3-phosphate de-
hydrogenase mRNA levels. Primers were designed as:
ALDH1 (forward, 5′-AATGGCATGATTCAGTGAGTG
GC-3′; reverse, 5′-GAGGAGTTTGCTCTGCTGGTTT








Statistical analysis was done using SPSS software version
11.0. Statistical differences were determined using a two-
tailed Student t test. The results were expressed as the
mean ± standard deviation. P<0.05 was considered statisti-
cally significant.
Results
Genistein inhibits breast cancer cells
We demonstrated the anti-proliferative effects of genis-
tein in the human MCF-7 breast cancer cell line with
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with increasing concentrations of genistein for 48 hours,
and the inhibitory effect was measured by the ratio of
inactive cells to the control (Figure 1A). Inactive cells in-
creased with elevated genistein concentration. The con-
centration that inhibits 50% of the growth of controlFigure 1 Genistein inhibits breast cancer cells. (A) MCF-7 cells growing
genistein for 48 hours. The anti-proliferation effect of genistein was measur
number of colonies in MCF-7 cells. Genistein’s effect on the surviving fracti
number of colonies was counted after 7 days. All data presented as mean ±
late period apoptotic cells labeled with Annexin V– fluorescein isothiocyan
repeated three times, and similar results were obtained. Representative sca
staining on the x axis and PI on the y axis. *P <0.05, Student’s t test. Each c
standard deviations.cells at 48 hours post treatment was 32.5 μM. The genis-
tein concentrations equivalent to the concentration that
inhibits 50% of the growth of control cells were then used
throughout the remainder of the study. Consistently the
survival cells decreased as the genistein dosage increased
(Figure 1B). The colony number was also reduced byin the log phase were treated with increasing concentrations of
ed by Cell Counting Kit-8 (CCK-8;) assay. (B), (C) Genistein reduced the
on on MCF-7 cells was detected by colony formation assay. The
standard deviation (n ≥3). (D) Genistein increased the percentage of
ate (FITC)/propidium iodide (PI) in MCF-7 cells. Experiments were
tter grams from flow cytometry profile represent Annexin V–FITC (AV)
ondition was repeated three times and error bars represent
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compared with the control group (Figure 1C). Further-
more, exposure of cells to genistein for 48 hours resulted
in an accumulation of apoptotic cells (Figure 1D). The in-
duction of apoptosis was in a dose-dependent manner.
Our results demonstrate that genistein had multiple ef-
fects on MCF-7 cell growth, proliferation, and apoptosis.
Genistein suppresses breast cancer stem cells in vitro
To investigate effects of genistein on the size and number
of the stem cell population, we performed the mammo-
sphere formation assay in human MCF-7 breast cancer
cells. BCSCs have been demonstrated to be enriched in
nonadherent spherical clusters of cells, termed mammo-
spheres [18], which in turn can give rise to the secondary
spheres and differentiate into multiple lineages. After treat-
ment with varying concentrations of genistein, the MCF-7
cells were harvested and subcultured for two passages in
the absence of genistein. As shown in Figure 2A,B, genis-
tein reduced both the number and size of mammospheres.
Both CD44+ and CD24– have been used as specific markers
to identify the BCSCs from human tumor tissues [19].
The CD44+CD24– cell population is capable of self-Figure 2 Genistein decreases breast cancer stem cells in vitro. (A), (B)
number (B) of mammospheres. MCF-7 cells were treated with different conce
plates with serum-free medium for 7 days. Mammospheres were collected an
stem-like cells was reduced by genistein treatment. The phenotype of CD44+/
obtained in three independent experiments, and the representative microsco
Student’s t test. FITC, fluorescein isothiocyanate; PE, phycoerythrin.renewal and generating tumors resembling breast can-
cer. However, there is no report of genistein effect on
MCF-7 BCSCs. We evaluated the CD44+CD24– cell
population in MCF-7 cells with fluorescence-activated
cell sorting after genistein treatment in vitro. As shown
in Figure 2C,D, the CD44+CD24– population in genistein-
treated MCF-7 cells was significantly decreased by 62%
(at 15 μM genistein) and 87% (at 30 μM genistein) re-
spectively, compared with the control (P <0.05). These
findings therefore demonstrate that genistein can sup-
press the BCSC population in vitro.
Genistein reduces breast cancer stem cells in vivo
Many studies have suggested that cancer stem cells may
contribute to the development of chemoresistance. To
determine whether genistein could have an effect on
BCSCs in vivo, we utilized a xenograft model of MCF-7
cells in nude mice. Two weeks after cell inoculation,
animals were randomly divided into three groups to re-
ceive daily intraperitoneal injection of 0.1% DMSO solu-
tion only (control group) or 20 and 50 mg/kg genistein
(dissolved in 0.1% DMSO solution). After 2 weeks of
treatment, the grafted tumors were dissected and weighed.Genistein decreased the size (A) (×200, scale bar = 100 μm) and
ntrations of genistein, and then were cultured in ultra-low-attachment
d evaluated. (C), (D) The percentage of CD44+/CD24– breast cancer
CD24– cells was measured by flow cytometry. Similar results were
pic picture and flow cytometry pattern are shown. *P <0.05, **P <0.01,
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treated mice were 46% and 68% of that in control animals
(P <0.05) (Figure 3A).
Since studies have shown that breast cancer cells
with high aldehyde dehydrogenase (ALDH) activity haveFigure 3 Genistein decreased breast cancer stem cells in vivo. (A) Gen
7 cells were inoculated into the mouse mammary fat pad for 2 weeks, and
of treatment, mice were sacrificed. Error bars represent standard deviations, n
isoform 1 (ALDH1) antibodies (brown in cytoplasm), ×200. (C) Real-time polym
(D) ALDH1 protein level before and after treatment with genistein. * P <0.05,
dehydrogenase.enriched tumorigenic stem cells [20], we examined the
ALDH levels in the tumors isolated from the three
groups by immunohistochemical staining and real-time
polymerase chain reaction. Genistein significantly re-
duced ALDH staining (Figure 3B), mRNA expressionistein remarkably reduced the tumor volume and weight: 1 × 106 MCF-
then were treated daily with 20 and 50 mg/kg genistein. After 2 weeks
= 5. (B) Immunohistochemistry staining with aldehyde dehydrogenase
erase chain reaction analyses of ALDH1 in the mouse tumor tissues.
**P <0.01, Student’s t test. GAPDH, glyceraldehyde 3-phosphate
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50% compared with that from control mice (P<0.05).
These results suggest that genistein was able to target
BCSCs to reduce the xenograft tumors.
Genistein inhibits breast cancer stem cells through
downregulation of the Hedgehog–Gli1 signaling pathway
We next investigated the mechanisms underlying the in-
hibitory effects of genistein on BCSCs. The Hedgehog
pathway is known to be an important regulator of stem
cell self-renewal. Emerging data from many human tu-
mors have suggested that Hedgehog–Gli1 signaling regu-
lates cancer stem cells [21]. Aberrant activation of SMO
and Gli1 are known as the key process of the Hedgehog–
Gli1 signaling pathway. As shown in Figure 4A, 30 μM
genistein significantly decreased the mRNA level of Smo
by 57% and of Gli1 by 59% in MCF-7 cells compared with
control. This was further confirmed with western blot ana-
lysis (Figure 4B).
To further investigate whether the Hedgehog–Gli1 path-
way was inhibited by genistein in vivo, we examined
mRNA levels and protein expression of Smo and Gli1 from
the tumors yielded from control and genistein-treated
mice. As shown in Figure 5A, the genistein treatment sig-
nificantly decreased the Smo-positive and Gli1-positive
staining in breast tumor tissues, compared with the control
group. Consistently, the mRNA level and protein level of
Smo and Gli1 also significantly decreased after genistein
treatment (Figure 5B,C). In summary, these results suggest
that genistein suppressed BCSCs by downregulating the
Hedgehog–Gli1 pathway.Figure 4 Hedgehog–Gli1 pathway inhibition by genistein in vitro. (A)
(SMO) and Gli1 in MCF-7 cells. The cells were incubated with different conc
were measured by western blot analysis in MCF-7 cells and accompanied b
3-phosphate dehydrogenase (GAPDH) was used for normalization. *P <0.05Discussion
In this study, we for the first time demonstrated that genis-
tein has multiple anti-breast cancer cell effects, not only
suppressing proliferation and inducing apoptosis of the
cancer cells, but also specifically inhibiting the cancer stem
cells by downregulating the Hedgehog–Gli1 pathway.
Cancer stem cells are currently believed to be the root
cause of cancer, which contribute to resistance to ther-
apy, tumor recurrence, and distant metastasis. However,
lack of efficacy of current chemotherapies in advanced
and metastatic disease requires novel approaches to spe-
cifically target the cancer stem cell population [22,23].
Therapies directed against both differentiated cancer
cells and cancer stem cells may thus provide advantages
to treat these diseases. The well-known curcumin and
sulforaphane were shown to interfere with Wnt signal-
ing pathway in cancer cells [10,11,17]. Some agents
such as sulforaphane, which regulates the Wnt/β-catenin
signaling pathway, have been shown to reduce the
BCSC population [10]. For the past few years, studies
have focused on efficacy of genistein, a predominant
isoflavone found in soy products, in various cancers, es-
pecially in the breast and prostate cancer. Genistein is
a well-characterized multifunctional soy isoflavone with
biological activities including protein tyrosine kinase
inhibition, estrogen receptor activation, and antioxidant
activity [15,24]. We therefore focus on the relationship
between genistein and BCSCs and the potential mech-
anism involved.
We first tested whether genistein has a killing effect
on MCF-7 breast cancer cells. Not surprisingly, genisteinReal-time polymerase chain reaction analysis of human Smoothened
entrations of genistein for 48 hours. (B) Protein levels of SMO and Gli1
y a quantitative bar chart. As an internal control, glyceraldehyde
, # P <0.05, **P <0.01, Student’s t test.
Figure 5 Hedgehog–Gli1 pathway inhibition by genistein in vivo. (A) Immunohistochemistry staining with human Smoothened (SMO) and
Gli1 antibodies (brown in cytoplasm), ×200. (B) Real-time polymerase chain reaction analysis of SMO and Gli1 in mice tumors. (C) Smo and Gli1
protein level in tumor tissue and accompanied by a quantitative bar chart. Data presented as mean ± standard deviation, n = 5. *P <0.05, **P <0.01,
Student’s t test. Each condition was repeated three times and error bars represent standard deviations. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase.
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ation, activation, and apoptosis. To study the cancer
stem cells, we decided to use mammosphere culture that
was first used to isolate and expand mammary stem/pro-
genitor cells by Dontu and colleagues [18], based on the
ability of stem cells to grow in serum-free suspension,
while differentiated cells fail to survive under the same
condition [25]. Using this technique, we demonstrated
that genistein (5 to 10 μM) significantly reduced both
the size and number of mammospheres formed by
MCF-7 cells. Another technique is to use cell markers to
distinguish BCSCs from differentiated cancer cells. As
few as 200 CD44+CD24−/lowlin− cells have been reported
to be able to generate a breast tumor [19]. We thus uti-
lized a CD44 and CD24 staining flow cytometry assay to
evaluate the ability of genistein to target BCSCs. Wedemonstrated that genistein specifically suppressed the
CD44+CD24– cell population in MCF-7 cells. These
findings support that genistein is effective in reducing
BCSCs in vitro.
The injection of human breast cancer cells into the
mammary fat pad of nude mice provides a reliable and
sensitive in vivo system for studying human breast can-
cer. We therefore tested whether genistein was able to
target BCSCs in vivo by using this xenograft model.
Daily injection of genistein for 2 weeks successfully sup-
pressed tumor growth in nude mice. We also examined
ALDH1 in these animals treated with or without genis-
tein. ALDH is another important marker for BCSCs. In
a previous study, 50,000 ALDH-negative cells failed
to form tumors, while <500 ALDH-positive cells were
able to generate a breast tumor within 40 days [20]. We
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tein and mRNA levels were significantly lower than
those in control group mice. These are consistent with
the in vitro observation that genistein specifically tar-
geted BCSCs. The capacity of genistein in killing BCSCs
may be significant for chemoprevention.
The Hedgehog gene was first discovered by Nusslein
Volhard and Wieschaus in Drosophila melanogaster lar-
vae, and has been shown critical for the self-renewal of
many cancer stem cells [26,27]. This signaling pathway
can be a simple conclusion of the Hedgehog–Ptch1–
Smo–Gli process. Gil1, which is independent of Smo ac-
tivation, is an important regulator of the effect of the
Hedgehog pathway on transcription. The proliferation of
cancer stem cells could be inhibited by a blockade of the
Hedgehog pathway due to the deletion of SMO or (and)
Gli1. In this study, we observed the reduced expression
of SMO and Gli1 after treatment with genistein both
in vitro and in vivo. In the presence of genistein, down-
regulation of the Hedgehog pathway may contribute to
the loss of stemness of BCSCs. This warrants further
studies (such as rescue experiment by overexpression of
SMO and Glil) to establish the conclusively causative
role of this downregulation in the inhibition of BCSCs
by genistein.
Conclusion
We demonstrate for the first time that genistein specific-
ally inhibits BCSCs, in association with downregulation
of the Hedgehog–Gli1 self-renewal pathway. Genistein, a
natural compound, has no reported toxic side effects,
and may provide a new safe and effective therapeutic
way for the treatment of breast cancer. This study thus
provides a strong rationale for investigating the chemo-
prevention entity of genistein in clinical trials.
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